Cargando…

Nemolizumab in moderate to severe atopic dermatitis: An exploratory analysis of work productivity and activity impairment in a randomized phase II study

Atopic dermatitis negatively impacts work productivity. This study investigated the impact of nemolizumab on work productivity and activity impairment in adults with moderate to severe atopic dermatitis inadequately controlled by topical treatments in a two‐part, phase II, randomized control trial....

Descripción completa

Detalles Bibliográficos
Autores principales:	Mihara, Ryosuke, Kabashima, Kenji, Furue, Masutaka, Nakano, Miwa, Ruzicka, Thomas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6771858/ https://www.ncbi.nlm.nih.gov/pubmed/31166620 http://dx.doi.org/10.1111/1346-8138.14934

Ejemplares similares

Nemolizumab Improves Patient-Reported Symptoms of Atopic Dermatitis with Pruritus: Post Hoc Analysis of a Japanese Phase III Randomized Controlled Trial
por: Kabashima, Kenji, et al.
Publicado: (2023)

Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents
por: Sidbury, Robert, et al.
Publicado: (2022)

Topical tacrolimus as treatment of atopic dermatitis
por: Furue, Masutaka, et al.
Publicado: (2009)

OX40L–OX40 Signaling in Atopic Dermatitis
por: Furue, Masutaka, et al.
Publicado: (2021)

Special Issue “Pathogenesis, Epidemiology and Treatment of Atopic Dermatitis and Psoriasis”
por: Furue, Masutaka
Publicado: (2021)

Current status of atopic dermatitis in Japan
por: Furue, Masutaka, et al.
Publicado: (2011)

Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate‐to‐severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long‐term studies
por: Kabashima, K., et al.
Publicado: (2021)

Aryl Hydrocarbon Receptor in Atopic Dermatitis and Psoriasis
por: Furue, Masutaka, et al.
Publicado: (2019)

Safety and Efficacy of Nemolizumab for Atopic Dermatitis With Pruritus: A Systematic Review and Meta-Regression Analysis of Randomized Controlled Trials
por: Liang, Junqin, et al.
Publicado: (2022)

Regulation of Filaggrin, Loricrin, and Involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: Pathogenic Implications in Atopic Dermatitis
por: Furue, Masutaka
Publicado: (2020)

Regulation of Skin Barrier Function via Competition between AHR Axis versus IL-13/IL-4‒JAK‒STAT6/STAT3 Axis: Pathogenic and Therapeutic Implications in Atopic Dermatitis
por: Furue, Masutaka
Publicado: (2020)

Modulation of Neuroimmune and Epithelial Dysregulation in Patients With Moderate to Severe Prurigo Nodularis Treated With Nemolizumab
por: Deng, Junwen, et al.
Publicado: (2023)

Nocturnal Scratching and Quality of Sleep in Children with Atopic Dermatitis
por: SUGIYAMA, Akiko, et al.
Publicado: (2023)

Glyteer, Soybean Tar, Impairs IL-4/Stat6 Signaling in Murine Bone Marrow-Derived Dendritic Cells: The Basis of Its Therapeutic Effect on Atopic Dermatitis
por: Takemura, Masaki, et al.
Publicado: (2018)

Patient-oriented Eczema Measure score: A Useful Tool for Web-Based Surveys in Patients with Atopic Dermatitis
por: KIDO-NAKAHARA, Makiko, et al.
Publicado: (2020)

Measurement of trihydroxy-linoleic acids in stratum corneum by tape-stripping: Possible biomarker of barrier function in atopic dermatitis
por: Chiba, Takahito, et al.
Publicado: (2019)

The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus
por: Rerknimitr, Pawinee, et al.
Publicado: (2017)

Nomenclature and clinical phenotypes of atopic dermatitis
por: Girolomoni, Giampiero, et al.
Publicado: (2021)

Impact of Atopic Dermatitis on Work and Activity Impairment in Taiwan
por: CHAN, Tom C., et al.
Publicado: (2021)

Role of ERK Pathway in the Pathogenesis of Atopic Dermatitis and Its Potential as a Therapeutic Target
por: Zeze, Nahoko, et al.
Publicado: (2022)

Nemolizumab efficacy in prurigo nodularis: onset of action on itch and sleep disturbances
por: Ständer, S., et al.
Publicado: (2022)

Aryl hydrocarbon receptor activation restores filaggrin expression via OVOL1 in atopic dermatitis
por: Tsuji, Gaku, et al.
Publicado: (2017)

IL-24 Negatively Regulates Keratinocyte Differentiation Induced by Tapinarof, an Aryl Hydrocarbon Receptor Modulator: Implication in the Treatment of Atopic Dermatitis
por: Vu, Yen Hai, et al.
Publicado: (2020)

Lebrikizumab for the Treatment of Moderate-to-Severe Atopic Dermatitis
por: Bernardo, Diana, et al.
Publicado: (2023)

The Relationship between Symptom Flare of Atopic Dermatitis and Airborne Japanese Cedar and Cypress Pollen Counts: A Self-Scoring Diary Study
por: Nishie, Haruko, et al.
Publicado: (2012)

Type 2 Inflammation Contributes to Skin Barrier Dysfunction in Atopic Dermatitis
por: Beck, Lisa A., et al.
Publicado: (2022)

Serum canine thymus and activation‐regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis
por: Asahina, Ryota, et al.
Publicado: (2020)

The ability of biomarkers to assess the severity of atopic dermatitis
por: Nakahara, Takeshi, et al.
Publicado: (2023)

Oxidative stress as a treatment target in atopic dermatitis: The role of furfuryl palmitate in mild-to-moderate atopic dermatitis
por: Hebert, Adelaide A.
Publicado: (2020)

IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis
por: Miake, Sho, et al.
Publicado: (2019)

Baricitinib: A Review in Moderate to Severe Atopic Dermatitis
por: Hoy, Sheridan M.
Publicado: (2022)

Association of Moderate–Severe Atopic Dermatitis with Dental Anomalies
por: Tan, Sean Y., et al.
Publicado: (2022)

A Case of Atopic Dermatitis with High Serum Levels of Anti-BP180 Antibody and Dyshidrosiform Blisters Limited to the Palms and Soles
por: KAISHO, Junichi, et al.
Publicado: (2021)

A Randomized, Open-Label, Multicenter Trial of Topical Tacrolimus for the Treatment of Pruritis in Patients with Atopic Dermatitis
por: Takeuchi, Satoshi, et al.
Publicado: (2012)

Exploratory analyses of biomarkers in blood and stratum corneum in patients with atopic dermatitis
por: Maruyama, Ayano, et al.
Publicado: (2022)

Efficacy and safety of dupilumab in Japanese adults with moderate‐to‐severe atopic dermatitis: a subanalysis of three clinical trials
por: Katoh, N., et al.
Publicado: (2019)

Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial
por: Reich, Kristian, et al.
Publicado: (2020)

Fetal Tobacco Smoke Exposure in the Third Trimester of Pregnancy Is Associated with Atopic Eczema/Dermatitis Syndrome in Infancy
por: Shinohara, Miwa, et al.
Publicado: (2017)

Exploring Immune Development in Infants With Moderate to Severe Atopic Dermatitis
por: Hulshof, Lies, et al.
Publicado: (2018)

Apremilast Use for Moderate-to-Severe Atopic Dermatitis in Pediatric Patients
por: Saporito, Rachael C., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s8j0nvjj7al6i71ie3iblek88e